In Silico Identification of Novel and Potent Inhibitors Against Mutant BRAF (V600E), MD Simulations, Free Energy Calculations, and Experimental Determination of Binding Affinity
Molecular Informatics · 2025
DOI: 10.1002/minf.202400372 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Informatics, 2025. Verfasst von Vikas Yadav und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Molecular Dynamics Simulation, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: School of Computational and Integrative Sciences, Jawaharlal Nehru University, DBT.
Abstract (Originalsprache)
BRAF is a proto oncogene that functions as a key signal transducer in the MAPK‐ERK pathway, which regulates cell growth, division, and survival. Mutations in BRAF, particularly the V600E substitution in its kinase domain, are major drivers in melanoma and several other metastatic cancers, including breast, colorectal, NSCLC, and gastrointestinal cancers. In this study, novel inhibitors targeting the BRAF(V600E) mutant using a structure‐based drug design approach are identified. Four chemical libraries ChemDiv Kinase, ChemDiv Anticancer, NCI, and ChEMBL Kinase SARfari are screened. Compounds from the ChemDiv Anticancer database show better Glide scores comparable to the FDA‐approved BRAF inhibitor Vemurafenib. The compounds P184‐1419 and P184‐1479 score −12.688 and −12.012 kcal/mol, respectively, versus −14.288 kcal/mol for Vemurafenib. Top hits are further validated using GOLD docking, X‐score ranking, and interaction profiling via LigPlot. Molecular dynamics simulations, principal component analysis, and free energy calculations confirm the stability of protein–ligand complexes. Biolayer interferometry assays reveal P184‐1419 exhibits stronger binding affinity (KD = 151 μM) than Vemurafenib (KD = 437 μM). These findings suggest P184‐1419 is a promising lead compound against BRAF(V600E), offering potential for future development of more effective cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Computational and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India.
- School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
ORCID-Profile: Vikas Yadav, Naidu Subbarao
Förderung
- School of Computational and Integrative Sciences
- Jawaharlal Nehru University
- DBT
Zitieren
APA
Yadav, V., Kashif, M., Kamali, Z., Gourinath, S., & Subbarao, N. (2025). In Silico Identification of Novel and Potent Inhibitors Against Mutant BRAF (V600E), MD Simulations, Free Energy Calculations, and Experimental Determination of Binding Affinity. Molecular Informatics. https://doi.org/10.1002/minf.202400372
Vancouver
Yadav V, Kashif M, Kamali Z, Gourinath S, Subbarao N. In Silico Identification of Novel and Potent Inhibitors Against Mutant BRAF (V600E), MD Simulations, Free Energy Calculations, and Experimental Determination of Binding Affinity. Molecular Informatics. 2025. doi:10.1002/minf.202400372
BibTeX
@article{Yadav2025,
author = {Yadav, Vikas and Kashif, Mohammad and Kamali, Zenab and Gourinath, Samudrala and Subbarao, Naidu},
title = {In Silico Identification of Novel and Potent Inhibitors Against Mutant BRAF (V600E), MD Simulations, Free Energy Calculations, and Experimental Determination of Binding Affinity},
journal = {Molecular Informatics},
year = {2025},
doi = {10.1002/minf.202400372}
}
EUVIMED